Nutra Pharma Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael D. Flax
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1537 NW 65th Avenue Boca Raton FL United States of America 33313
- IPO Date
- Dec 6, 2001
- CIK
- 0001119643
- Website
- nutrapharma.com
- Similar Companies
- Business
- Nutra Pharma Corp. operates as a biopharmaceutical enterprise, concentrating on the acquisition, licensing, and commercialization of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical drugs. The company's efforts primarily address the management of pain, a spectrum of neurological disorders, various cancers, autoimmune conditions, and infectious diseases, mainly within the United States. Among its marketed offerings are Nyloxin and Cobroxin products, available as oral sprays and topical gels designed to alleviate various discomforts such as lower back pain, migraines, neck and shoulder aches, cramps, and neuropathic conditions, alongside joint pain, arthritis, and repetitive stress. The company also provides Pet Pain-Away, a homeopathic, non-addictive over-the-counter solution for chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever specifically formulated for discomfort caused by high heels; and Equine Pain-Away, a topical pain management product for horses. Additionally, it offers specialized formulations like Nyloxin Military Strength for use by the United States Military and Veteran's Administration. In its development pipeline, Nutra Pharma is advancing RPI-78M for neurological and autoimmune disorders, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis. RPI-MN is under investigation for viral conditions such as human immunodeficiency virus/AIDS and herpes, as well as broader anti-viral applications. Further compounds include RPI-78 and RPI-70, both targeting pain and arthritis relief. Recent efforts also include advancing RIMSO-50 as an oral solution aimed at alleviating opioid-induced constipation, and exploring nerve agent countermeasures. Following a settlement with the U.S. Securities and Exchange Commission in March 2024, the company saw its former Chief Executive Officer, Rik J Deitsch, tender his resignation, with Dr. Michael Flax resuming the roles of Chairman and CEO. Under its renewed leadership, Nutra Pharma is focusing on expanding its operations, with plans for new retail rollouts, conducting further clinical trials for its ethical drugs, and enhancing its contract manufacturing capabilities at its facility in Boca Raton, Florida. The firm, established in 2000, maintains its corporate headquarters in Boca Raton, Florida.
Nutra Pharma (OTCMKTS:NPHC) versus XOMA Royalty (NASDAQ:XOMA) Head-To-Head Review
REPORT: Buganda, Ankole & Busoga Regions Getting Highest Remittances From Abroad
Why SPA Mutyabule believes census is a good tool in combating poverty in Busoga
Nutra Pharma Corp. Reaches Settlement with SEC
Nutra Pharma Corp. Reaches Settlement with SEC
Nutra Pharma Provides Business and Compliance Updates
Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures
Nutra Pharma Engages Government Affairs Consulting Firm
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers
Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers
Professional Snowboarder Jake Vedder Joins Nutra Pharma in Endorsing Nyloxin for Chronic Pain Relief
Nutra Pharma Provides Updates on Improvements of Manufacturing Capabilities
Nutra Pharma Announces Influencer and Social Media Campaign for Nyloxin and Pet Pain-Away
Nutra Pharma Announces Distribution of Luxury Feet for the Relief of Pain from High Heels
Nutra Pharma Announces Distribution of Luxury Feet for the Relief of Pain from High Heels
Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications
Nutra Pharma Announces New Intellectual Property Update and Engages Additional Intellectual Property Attorneys